Processa Pharmaceuticals (PCSA) Capital Expenditures (2012 - 2015)
Processa Pharmaceuticals' (PCSA) quarterly Capital Expenditures came in at $1399.0 in Q1 2015, down 89.84% YoY from $13772.0 in Q1 2014, and up 109.51% on a QoQ basis from -$14712.0 in Q4 2014.
Processa Pharmaceuticals (PCSA) Capital Expenditures (2012 - 2015) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 4 years of Capital Expenditures data on file, last reported at $1399.0 in Q1 2015.
- Quarterly Capital Expenditures fell 89.84% year-over-year to $1399.0 in Q1 2015, while the trailing twelve-month figure through Dec 2015 was $1399.0 (down 87.29% YoY) and the FY2024 annual result came in at $3244.0, up 16.86% from the prior year.
- Capital Expenditures improved to $1399.0 in Q1 2015, from -$14712.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $244273.0 in Q3 2012 to a low of -$14712.0 in Q4 2014.
- A 4-year average of $27157.2 and a median of $6276.0 in 2013 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 119.44% in 2014, down 1471300.0% in 2014.
- Tracing PCSA's Capital Expenditures over 4 years: stood at $14376.0 in 2012, then plunged by 99.99% to $1.0 in 2013, then slumped by 1471300.0% to -$14712.0 in 2014, then surged by 109.51% to $1399.0 in 2015.
- The last three Capital Expenditures figures came in at $1399.0 (Q1 2015), -$14712.0 (Q4 2014), and $9947.0 (Q3 2014), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 34.68 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.26 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 251.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -73.57 Mn |
| 10 | Processa Pharmaceuticals | 5.93 Mn | 5.93 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2015 | 1,399.00 |
| Mar 31, 2015 | 1,399.00 |
| Dec 31, 2014 | -14,712.00 |
| Dec 31, 2014 | -14,712.00 |
| Sep 30, 2014 | 9,947.00 |
| Sep 30, 2014 | 9,947.00 |
| Jun 30, 2014 | 2,000.00 |
| Jun 30, 2014 | 2,000.00 |
| Mar 31, 2014 | 13,772.00 |
| Mar 31, 2014 | 13,772.00 |
| Dec 31, 2013 | 1.00 |
| Dec 31, 2013 | 1.00 |
| Sep 30, 2013 | 20,341.00 |
| Sep 30, 2013 | 20,341.00 |
| Jun 30, 2013 | 1,056.00 |
| Jun 30, 2013 | 1,056.00 |
| Mar 31, 2013 | 6,276.00 |
| Mar 31, 2013 | 6,276.00 |
| Dec 31, 2012 | 14,376.00 |
| Dec 31, 2012 | 14,376.00 |